Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A01349 | Pages: 233 | Charts: 43 | Tables: 121 |
The global smart insulin or glucose responsive insulin market size was valued at $2,773.73 million in 2019, and is expected to reach $6,174.30 million by 2027, registering a CAGR of 10.5% from 2020 to 2027. Smart insulin or glucose-responsive insulin is the next generation insulin that automatically responds to changing blood glucose levels. These products help in management of blood glucose level of diabetic patients in minimally invasive manner. Smart insulin works accordingly in response to blood glucose concentration i.e. higher the blood glucose higher is the concentration of insulin released and lower the blood glucose lower is the concentration of insulin released. It is a painless mode of introducing insulin compared to injectable insulin, reducing the risk of skin irritation caused due to needles.In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. The development of smart insulin is accelerating the growth of healthcare and digital science leading to cures and treatments of patients with Type 1 and Type 2 diabetes by advance upcoming approaches.
The market is expected to witness an exponential growth during the forecast period, owing to the benefits of using these advanced devices over conventional products and rise in healthcare expenditure. As per data published by the NCBI (National Center for Biotechnology Information) in 2016, six million people with diabetes used insulin either alone or in combination with an oral medication. Moreover, increase in disposable income among t diabetic patients and technological advancements of smart insulin products are anticipated to fuel the market growth.However, lack of awareness, cost restrains in developing regions, and less variability in products are expected to hinder the market growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to provide opportunities for the smart insulin or glucose responsive insulin market growth.
Get more information on this report : Request Sample Pages
The smart insulin or glucose responsive insulin market is segmented on the basis of type, disease, delivery devices, and region. By type, it is divided into rapid-acting, intermediate-acting, long-acting, short-acting and pre-mixed type. On the basis of disease, the market is bifurcated into Type 1 and Type 2 diabetes. On the basis of delivery devices, the smart insulin or glucose responsive insulin market is classified into smart insulin pen and smart insulin pump. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
[DELIVERYDEVICEGRAPH]
Get more information on this report : Request Sample Pages
By delivery devices, the smart insulin pumps segment accounted for 96% of the total market share in 2019, and is expected to exhibit a prominent growth rate in the future, owing to its increased adoption across the globe for diabetes. In addition, smart insulin pumps release small doses of insulin continuously, meanwhile patients can adjust the amount of insulin to be released pre and post mealtime by configuring the pump.
[DISEASEGRAPH]
Get more information on this report : Request Sample Pages
By disease type, type 2 diabetes cases are much more than type 1 diabetes. Most of the products used in the market areeither used for both types of diabetes or only for type 2. Type 2 diabetes is the most important contributor toward the market growth. Moreover, as patients suffering from type 2 diabetes are increasing at a higher rate, it is anticipated to be the fastest growing segment during the forecast period.
[TYPEGRAPH]
Get more information on this report : Request Sample Pages
By type, the rapid acting segment is anticipated to grow at a significant rate during the forecast period. Rapid-acting insulin is one of the fastest acting insulins that start working in 15 minutes of its introduction in the body. The activity of this insulin is supposed to last for 5 hours. Some of the rapid-acting insulin available in the market are Humalog, Flaps and Novo Rapid, and Apia. Rapid-acting insulin are usually preferred in pumps that deliver little amounts of insulin into the body every few minutes.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
North America accounted for the majority of the smart insulin or glucose responsive insulin market share in 2019, and is anticipated to continue this trend during the forecast period. North America holds a dominant share in the global smart insulin or glucose responsive insulin market, owing to well-developed supply-side infrastructure, rapid acceptance of innovative technologies, and adequate reimbursements (as compared to other regions).
Comprehensive competitive analysis and profiles of major smart insulin or glucose responsive insulin market players such as CeQur, Diamesco Co, Eli lily and Company, Insulet Corporation, Medtronic Plc, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Sanofi and Zealand Pharma are provided in this report.
Key Benefits For Stakeholders
Key Market Segments
By Delivery Devices
By Disease
By Type
By Geography
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market Definition and Scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s Five Forces Analysis
3.4.Market Dynamics
3.4.1.Drivers
3.4.1.1.Surge in incidence and prevalence of diabetes
3.4.1.2.Rise in healthcare expenditure
3.4.1.3.Increased adoption of technologically advanced products
3.4.2.Restraints
3.4.2.1.Adverse effects of smart insulin devices
3.4.2.2.Safety Issues with Devices
3.4.3.Opportunities
3.4.3.1.Increase in awareness toward smart insulin devices
3.4.3.2.Untapped opportunities and undiagnosed population in developing regions
3.4.4.Market Trends
CHAPTER 4:SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DELIVERY DEVICES
4.1.Overview
4.1.1.Market size and forecast
4.2.Smart Insulin Pens
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Smart Insulin Pumps
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.3.4.Types of Smart Insulin Pumps
4.3.5.Market size and forecast
4.3.6.Tethered insulin Pumps
4.3.7.Insulin Patch Pumps
CHAPTER 5:SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DISEASE
5.1.Overview
5.1.1.Market size and forecast, by disease
5.2.Type 1 Diabetes
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Type 2 Diabetes
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Rapid-acting Insulin
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Short-acting Insulin
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Intermediate-acting Insulin
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.Long-acting Insulin
6.5.1.Market size and forecast
6.5.2.Market analysis, by country.
6.6.Pre-mixed Insulin
6.6.1.Market size and forecast
6.6.2.Market analysis, by country.
CHAPTER 7:SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by delivery device
7.2.4.Market size and forecast, by disease
7.2.5.Market size and forecast, by type
7.2.6.1.U.S. market size and forecast, by delivery device
7.2.6.2.U.S. market size and forecast, by disease
7.2.6.3.U.S. market size and forecast, by type
7.2.6.4.Canada market size and forecast, by delivery device
7.2.6.5.Canada market size and forecast, by disease
7.2.6.6.Canada market size and forecast, by type
7.2.6.7.Mexico market size and forecast, by delivery device
7.2.6.8.Mexico market size and forecast, by disease
7.2.6.9.Mexico market size and forecast, by type
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by delivery device
7.3.4.Market size and forecast, by disease
7.3.5.Market size and forecast, by type
7.3.5.1.Germany market size and forecast, by delivery device
7.3.5.2.Germany market size and forecast, by disease
7.3.5.3.Germany market size and forecast, by type
7.3.5.4.France market size and forecast, by delivery device
7.3.5.5.France market size and forecast, by disease
7.3.5.6.France market size and forecast, by type
7.3.5.7.UK market size and forecast, by delivery device
7.3.5.8.UK market size and forecast, by disease
7.3.5.9.UK market size and forecast, by type
7.3.5.10.Italy market size and forecast, by delivery device
7.3.5.11.Italy market size and forecast, by disease
7.3.5.12.Italy market size and forecast, by type
7.3.5.13.Spain market size and forecast, by delivery device
7.3.5.14.Spain market size and forecast, by disease
7.3.5.15.Spain market size and forecast, by type
7.3.5.16.Rest of Europe market size and forecast, by delivery device
7.3.5.17.Rest of Europe market size and forecast, by disease
7.3.5.18.Rest of Europe market size and forecast, by type
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by delivery device
7.4.4.Market size and forecast, by disease
7.4.5.Market size and forecast, by type
7.4.5.1.Japan market size and forecast, by delivery device
7.4.5.2.Japan market size and forecast, by disease
7.4.5.3.Japan market size and forecast, by type
7.4.5.4.China market size and forecast, by delivery device
7.4.5.5.China market size and forecast, by disease
7.4.5.6.China market size and forecast, by type
7.4.5.7.Australia market size and forecast, by delivery device
7.4.5.8.Australia market size and forecast, by disease
7.4.5.9.Australia market size and forecast, by type
7.4.5.10.India market size and forecast, by delivery device
7.4.5.11.India market size and forecast, by disease
7.4.5.12.India market size and forecast, by type
7.4.5.13.South Korea market size and forecast, by delivery device
7.4.5.14.South Korea market size and forecast, by disease
7.4.5.15.South Korea market size and forecast, by type
7.4.5.16.Rest of Asia-Pacific market size and forecast, by delivery device
7.4.5.17.Rest of Asia-Pacific market size and forecast, by disease
7.4.5.18.Rest of Asia-Pacific market size and forecast, by type
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by delivery device
7.5.4.Market size and forecast, by disease
7.5.5.Market size and forecast, by type
7.5.5.1.Brazil market size and forecast, by delivery device
7.5.5.2.Brazil market size and forecast, by disease
7.5.5.3.Brazil market size and forecast, by type
7.5.5.4.Saudi Arabia market size and forecast, by delivery device
7.5.5.5.Saudi Arabia market size and forecast, by disease
7.5.5.6.Saudi Arabia market size and forecast, by type
7.5.5.7.South Africa market size and forecast, by delivery device
7.5.5.8.South Africa market size and forecast, by disease
7.5.5.9.South Africa market size and forecast, by type
7.5.5.10.Rest of LAMEA market size and forecast, by delivery device
7.5.5.11.Rest of LAMEA market size and forecast, by disease
7.5.5.12.Rest of LAMEA market size and forecast, by type
CHAPTER 8:COMPANY PROFILES
8.1.CEQUR
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.2.DIAMESCO CO., LTD.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.3.ELI LILY AND COMPANY
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.F. HOFFMANN-LA ROCHE LTD.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance.
8.5.INSULET CORPORATION
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.NOVO NORDISK A/S
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.MEDTRONIC PLC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.SANOFI
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.TANDEM DIABETES CARE, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.ZEALAND PHARMA A/S
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.STRATEGIC DEVELOPMENTS – PRODUCT APPROVAL (2017 – 2020)
TABLE 02.STRATEGIC DEVELOPMENTS – COLLABORATION (2017 – 2020)
TABLE 03.STRATEGIC DEVELOPMENTS – AGREEMENT (2017 – 2020)
TABLE 04.STRATEGIC DEVELOPMENTS – ACQUSITION (2017 – 2020)
TABLE 05.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DELIVERY DEVICES, 2019–2027 ($MILLION)
TABLE 06.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR SMART INSULIN PENS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR SMART INSULIN PUMPS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DELIVERY DEVICES, 2019–2027 ($MILLION)
TABLE 09.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DISEASE, 2019 - 2027 ($MILLION)
TABLE 10.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2019 - 2027 ($MILLION)
TABLE 11.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET TYPE 1 DIABETES, BY REGION, 2019 - 2027 ($MILLION)
TABLE 12.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR RAPID-ACTING INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR SHORT-ACTING INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN,BY REGION, 2019–2027 ($MILLION)
TABLE 16.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR LONG-ACTING INSULIN,BY REGION, 2019–2027 ($MILLION)
TABLE 17.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET FOR PRE-MIXED INSULIN,BY REGION, 2019–2027 ($MILLION)
TABLE 18.SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 19.NORTH SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 21.NORTH AMERICA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 22.NORTH AMERICA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 23.U.S SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 24.U.S. SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 25.U.S. SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 26.CANADA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 27.CANADA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 28.CANADA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 29.MEXICO SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 30.MEXICO SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 31.MEXICO SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 32.EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 33.EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 34.EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 35.EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 36.GERMANY SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 37.GERMANY SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 38.GERMANY SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 39.FRANCE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 40.FRANCE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 41.FRANCE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 42.UK SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 43.UK SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 44.UK SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 45.ITALY SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 46.ITALY SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 47.ITALY SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 48.SPAIN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 49.SPAIN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 50.SPAIN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 51.REST OF EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 52.REST OF EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 54.ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 55.ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027, ($MILLION)
TABLE 56.ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027, ($MILLION)
TABLE 57.ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027, ($MILLION)
TABLE 58.JAPAN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 59.JAPAN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 60.JAPAN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 61.CHINA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 62.CHINA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 63.CHINA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 64.AUSTRALIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 65.AUSTRALIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 67.INDIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 68.INDIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 69.INDIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 70.SOUTH KOREA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 71.SOUTH KOREA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 72.SOUTH KOREA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 76.LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 77.LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027, ($MILLION)
TABLE 78.LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027, ($MILLION)
TABLE 79.LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027, ($MILLION)
TABLE 80.BRAZIL SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 81.BRAZIL SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 82.BRAZIL SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 83.SAUDI ARABIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 84.SAUDI ARABIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 85.SAUDI ARABIA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 86.SOUTH AFRICA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 87.SOUTH AFRICA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 88.SOUTH AFRICA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 89.REST OF LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DELIVERY DEVICE, 2019–2027 ($MILLION)
TABLE 90.REST OF LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY DISEASE, 2019–2027 ($MILLION)
TABLE 91.REST OF LAMEA SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET BY TYPE, 2019–2027 ($MILLION)
TABLE 92.CEQUR: COMPANY SNAPSHOT
TABLE 93.CEQUR: PRODUCT SEGMENTS
TABLE 94.CEQUR: PRODUCT PORTFOLIO
TABLE 95.DIAMESCO: COMPANY SNAPSHOT
TABLE 96.DIAMESCO: OPERATING SEGMENTS
TABLE 97.DIAMESCO: PRODUCT PORTFOLIO
TABLE 98.ELI LILLY: COMPANY SNAPSHOT
TABLE 99.LILLY: OPERATING SEGMENTS
TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
TABLE 101.ROCHE: COMPANY SNAPSHOT
TABLE 102.ROCHE: OPERATING SEGMENTS
TABLE 103.ROCHE: PRODUCT PORTFOLIO
TABLE 104.INSULET: COMPANY SNAPSHOT
TABLE 105.INSULET: OPERATING BUSINESS SEGMENTS
TABLE 106.INSULET: PRODUCT PORTFOLIO
TABLE 107.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 108.NOVO NORDISK: OPERATING BUSINESS SEGMENTS
TABLE 109.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 110.MEDTRONIC: COMPANY SNAPSHOT
TABLE 111.MEDTRONIC: OPERATING BUSINESS SEGMENTS
TABLE 112.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 113.SANOFI: COMPANY SNAPSHOT
TABLE 114.SANOFI: OPERATING SEGMENTS
TABLE 115.SANOFI: PRODUCT PORTFOLIO
TABLE 116.TANDEM: COMPANY SNAPSHOT
TABLE 117.TANDEM: OPERATING SEGMENTS
TABLE 118.TANDEM: PRODUCT PORTFOLIO
TABLE 119.ZEALAND: COMPANY SNAPSHOT
TABLE 120.ZEALAND: OPERATING SEGMENTS
TABLE 121.ZEALAND: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.SEGMENTATION OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET
FIGURE 02.TOP INVESTMENT POCKETS IN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.MODERATE: BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE: BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW: THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE: THREAT OF SUBSTITUTION
FIGURE 10.HIGH: COMPETITIVE RIVALRY
FIGURE 11.RESTRAINTS AND DRIVERS: SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET
FIGURE 12.PREVALENCE OF DIABETES IN POPULATION (MILLIONS) AND DIABETES PREVALENCE (%)
FIGURE 13.DIABETES RELATED HEALTH EXPENDITURE ($ BILLION), 2019
FIGURE 14.DIABETES RELATED HEALTH EXPENDITURE ($ BILLION), 2019
FIGURE 15.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR SMART INSULIN PEN BY COUNTRY, 2019 & 2028(%)
FIGURE 16.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR SMART INSULIN PUMPS BY COUNTRY, 2019 & 2028(%)
FIGURE 17.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR TYPE 1 DIABETES BY COUNTRY, 2019 & 2028(%)
FIGURE 18.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR TYPE 1I DIABETES BY COUNTRY, 2019 & 2028(%)
FIGURE 19.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR RAPID-ACTING INSULIN BY COUNTRY, 2019 & 2028(%)
FIGURE 20.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR SHORT-ACTING INSULIN BY COUNTRY, 2019 & 2028(%)
FIGURE 21.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR INTERMEDIATE ACTING INSULIN BY COUNTRY, 2019 & 2028(%)
FIGURE 22.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR LONG-ACTING INSULIN BY COUNTRY, 2019 & 2028(%)
FIGURE 23.COMPARATIVE ANALYSIS OF SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET, FOR PREMIXED ACTING BY COUNTRY, 2019 & 2028(%)
FIGURE 24.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.ELI LILLY: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 26.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.INSULET: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.INSULET: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.INSULET: REVENUE SHARE BY REGION, 2019(%)
FIGURE 32.NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 34.NOVO NORDISK: REVENUE SHARE BY REGION, 2019(%)
FIGURE 35.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 37.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38.SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 40.SANOFI: REVENUE SHARE BY REGION, 2019(%)
FIGURE 41.TANDEM: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.TANDEM: REVENUE SHARE BY REGION, 2019(%)
FIGURE 43.ZEALAND: NET SALES, 2017–2019 ($MILLION)
